Endothelin-1 potentiation of coronary artery contraction after ischemia-reperfusion

Vascul Pharmacol. 2008 Feb-Mar;48(2-3):109-14. doi: 10.1016/j.vph.2008.01.003. Epub 2008 Jan 18.

Abstract

Hearts from Sprague-Dawley rats were perfused at constant flow and then exposed to 30 min global zero-flow ischemia followed by 15 min reperfusion. After ischemia-reperfusion, coronary arteries were dissected from the heart and segments 2 mm long were prepared for isometric tension recording in organ baths. Stimulation of the arteries with 5-hydroxytryptamine (10(-6) M) produced contraction, which was potentiated by treatment with endothelin-1 (3x10(-10); 10(-9) M). This potentiation was lower in the arteries from hearts after ischemia-reperfusion (for 3x10(-10) M, 15+/-5%; P>0.05; for 10(-9) M, 37+/-7%, P<0.01, n=5) than after control (for 3x10(-10) M, 34+/-4%; P<0.01; for 10(-9) M, 50+/-6%, P<0.01, n=5), and the potentiation was reduced by the inhibitor of nitric oxide synthesis l-NAME (10(-4) M), the antagonist of endothelin ET(A) receptors BQ123 (10(-6) M) and the antagonist of endothelin ET(B) receptors BQ788 (10(-6) M), but not by the cyclooxygenase inhibitor meclofenamate (10(-5) M). These results suggest that endothelin-1 at low concentrations potentiates coronary vasoconstriction, and this effect is reduced after ischemia-reperfusion, mediated by endothelin ET(A) and ET(B) receptors and dependent on nitric oxide release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Animals
  • Coronary Vessels / drug effects
  • Coronary Vessels / enzymology
  • Coronary Vessels / metabolism*
  • Coronary Vessels / physiopathology
  • Cyclooxygenase Inhibitors / pharmacology
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Endothelin-1 / metabolism*
  • Enzyme Inhibitors / pharmacology
  • In Vitro Techniques
  • Male
  • Meclofenamic Acid / pharmacology
  • Myocardial Reperfusion Injury / metabolism*
  • Myocardial Reperfusion Injury / physiopathology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / metabolism
  • Oligopeptides / pharmacology
  • Peptides, Cyclic / pharmacology
  • Perfusion
  • Piperidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Endothelin A / metabolism
  • Receptor, Endothelin B / metabolism
  • Serotonin / pharmacology
  • Vasoconstriction* / drug effects
  • Vasoconstrictor Agents / pharmacology

Substances

  • Cyclooxygenase Inhibitors
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Endothelin-1
  • Enzyme Inhibitors
  • Oligopeptides
  • Peptides, Cyclic
  • Piperidines
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Vasoconstrictor Agents
  • Serotonin
  • BQ 788
  • Meclofenamic Acid
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Nitric Oxide Synthase
  • cyclo(Trp-Asp-Pro-Val-Leu)
  • NG-Nitroarginine Methyl Ester